FRCP ED, associate professor of pharmacology drug; how it is expected to help; and how to recognise problems and what to do about them. A guide was designed to specify what information is required to meet these needs. Using this guide, a set of minimum information on tetracycline was prepared that aimed at being brief, specific, and readable. The best format for the information remains to be determined.
Superinfection by resistant organisms may follow suppression of the normal bacterial flora in the gastrointestinal tract. Overgrowth with Candida albicans can lead to sore mouth, anorectal inflammation, diarrhoea, and vaginitis. Resistant coliform organisms or staphylococci may cause life-threatening infection in debilitated patients and in those receiving immunosuppressive or corticosteroid therapy.
Renal toxicity-In patients who develop renal insufficiency while taking the drug it may seriously worsen renal function.
Acute benign intracranial hypertension (pseudotumur cerebri) sometimes follows the use of tetracycline in therapeutic doses in infants; they become irritable, vomit, and develop a tense bulging fontanelle. Adults show meningeal irritation and papilloedema. The spinal fluid is normal and the condition disappears when the drug is stopped.
Hepatotoxicity-Liver damage may follow intravenous use of tetracycline in large doses and has occasionally followed oral use. Such damage (which can be fatal) is more likely to occur in patients with pre-existing hepatic or renal insufficiency, particularly in pregnancy or post partum.
Photosensitivity reactions may occur and manifest as exaggerated sunburn and marked erythema on exposure to sunlight.
Hypersensitivity reactions may take the form of fixed eruptions, urticaria, angioneurotic oedema, non-thrombocytopenic purpura, and rarely anaphylactic shock.
Changes in children's teeth and nails-All tetracyclines are deposited in growing deciduous and permanent teeth, causing yellowish discoloration, enamel hypoplasia and tendency to caries if given to women after the 6th month of pregnancy and to children up to the age of 8 years. They are also deposited in the nails when given to infants and late in pregnancy. The incidence and intensity is related to the total dose of tetracyclines ingested.
Interactions Milk, iron, calcium, magnesium, and aluminium salts (present in many antacid preparations) diminish the absorption of tetracycline and therefore none of these should be given at the same time. Oral anticoagulants are potentiated because the drug inhibits vitamin Ksynthesising bacteria in the gut. The doses of the oral anticoagulant may thus have to be reduced during tetracycline therapy.
The anaesthetic methoxyflurane has precipitated fatal kidney failure in patients taking tetracycline, and should therefore be avoided. that show the effect, let alone the effectiveness, of giving information to patients. Much investigation and experiment will be needed before we can expect to identify useful ways of providing information about medicines to different groups of patients. Such investigations must concern: the information content; the style and format of presentation; and the circumstances and setting in which the patient receives the information. It is logical to begin by considering information content, and we therefore tried to determine what minimum information a patient needs. Our approach is based on earlier work done on minimum information for sensible use of self-prescribed medicines,' and on minimum information needed by prescribers.' We began by designing a general guide for constructing information sets for drugs, before assembling information sets for individual drugs. Both the guide and some model sets on individual drugs could be developed by international consensus. We used a draft guide to write information sets for three drugs. The set for tetracycline appears in the appendix; those for propranolol and prescribed aspirin are available from the authors.
The guide
The guide describes what a patient can do to make his treatment as effective and safe as possible (see table) . It lists the types of information that would enable him to do so, and thus provides clear reasons for including specific items in the set of minimum information for an individual drug. The report on minimum information for selfprescribed medicines' suggested that a consensus on minimum information could also be reached for prescribed medicines. But it pointed to the difficulty of finding a universally acceptable demarcation of responsibilities between doctor and patient. Once the patient's responsibilities have been defined, they can be expressed in terms of what he will actually have to do, and from that it follows what information, and how much, he needs.
TO KNOW HOW TO TAKE THE DRUG
That the patient should know how to take the drug is obvious. This means that he must know the dose (1.1) and the manner (1.2) and time (1.3) of taking the dose. It is uncertain how much the patient needs to know about his dose. Often it is enough for him to know, as patients do now from the label, that he should take "two tablets" or "one medicine-spoonful." But sometimes he needs to know the exact dose (1.1.1). The specific manner in which a dose is to be taken (1.2.1) is often important and even critical. The manner may be dictated by a dosage form, such as enteric-coated tablets which must be swallowed whole (and never taken with milk), or soluble tablets which must be dissolved before taking. It may also be dictated by the drug-for example, tetracycline, which must not be taken with milk, or sulphonamides, which must be taken with large amounts of water. Patients are rarely told the specific time at which the dose should be taken. Yet some drugs are best taken at a particular time of day (1.3.1), such as prednisolone for maintenance treatment (a single morning dose), and those for which the patient needs help in timing his doses, when he has been told only to take the dose "three times daily." If it were ampicillin, he could be told to take it every eight hours. The interval between doses (1.3.2) would also be much clearer for any medicine that is to be taken "as needed." To give the patient the information on the necessary interval between dose and food intake (1. of the drug. The style and format in which the information is finally presented should aim at brevity, specificity, and readability. Typography, layout, and other aspects of design are important. The cultural and psychological make-up of the patients must be considered. And even before all that, one must decide whether one wants patients to remember the information or to use it only "as needed." In designing experiments that evaluate the information, retention of facts has often been accepted as a measure of success for giving information.
Perhaps the process of giving information has been needlessly encumbered by regarding the drug information sheet as a text to be learnt rather than as reference material.
The example for tetracycline (see appendix) shows a format that presents the information for use "as needed." Readability and specificity are most important. The heading introduces the use of the information sheet, and sets the tone of directness and informality. The medicine is fully identified by giving the generic name and the names of the locally available brands. This is meant to reassure the patient, who may know only the brand name, that the information indeed applies to his medicine. The four sections of the information correspond to the four areas of responsibility. General terms are further interpreted-for example, "on an empty stomach" is changed to "no later than one hour before or no sooner than two hours after meals." Although patients are commonly warned about problems that may occur with their medicine, they are rarely told what they should do about them. The information sets include specific directions, which clearly state not only whether the patient should seek help, but also how urgently and from whom. For example, in the case of aspirin, the patient would be told to take the tablets with food or milk if he has stomach discomfort, but to stop taking aspirin and to tell the doctor if such discomfort is severe or prolonged. Patients are told to talk to the pharmacist -before taking additional medicines and to contact the nearest hospital casualty department in case of accidental overdose. For the overdose, "immediate" action is necessary. For some unwanted effects, such as a pulse slower than 55 beats per minute while on propranolol, the doctor should be "told promptly," but if minor side effects occur, such as nausea or sleeplessness, the doctor need only be "informed."
In summary, style and format were chosen to support the intent of the guide. Their usefulness needs to be validated when the effectiveness of the information sets is assessed.
Relation to other information for patients
The minimum information package is intended for the patient who has been given a specific medicine. Nevertheless, the patient may need other information at other times. For example, just before the doctor considers prescribing at all, doctor and patient both need to consider the likely benefits, contraindications and risks, inconveniences, and possible costs of the various choices. Ideally, the doctor will inform and guide the patient on these matters within the limits of the patient's ability. The doctor has been shown to be the person from whom patients are most likely to accept information on medicines, and for practical purposes it is best given at the time of prescribing. If the patient gets the information later he has been denied his chance to use it, since he has already accepted the treatment.
Rarely will a patient be so determined that he will reject the medicine that has already been dispensed, return to the doctor and ask for something else. It would indeed be best if patients learnt to expect this information during the consultation and asked the doctor about points that they have not fully understood. A list of 4uestions about medicines that patients may wish to ask the doctor has been suggested. 4 If patients were to get used to considering benefits, risks, and inconveniences with their doctor, they would probably consider the same points when choosing self-prescribed (over-the-counter) medicines.' In the pharmacy the patient may also need more information. Pharmacists are in-an excellent position to know what medicines the patient is taking, since they may dispense all the prescriptions a patient receives and know what self-prescribed medicines he uses. Pharmacists can protect patients from harmful interactions. Ideally, the pharmacist will also help with information on cost and equivalence of alternative preparations, especially when patients pay for the medicine and wish to spend as little as possible.
Who should be responsible for providing sets of minimum information for patients?
Patients have seldom been given information on individual medicines. A few package inserts for patients exist. In countries where inserts originally intended for doctors are given to patients, manufacturers have amended them to make them more useful to patients. But manufacturers have to work under constraints which make it difficult to produce sets of minimum information such as we have proposed. For example, it may be illegal to refer to existing medical uses that have not yet been accepted by the regulatory agency. On the other hand, manufacturers have been obliged to list every adverse effect, and listings have become excessively comprehensive. Professional organisations have also designed information leaflets, but these have generally not covered individual drugs, nor have they been generally available for distribution.
We therefore believe that, as with the minimum information for prescribers,' sets of minimum information for patients should be put together by a small independent group, consisting of clinical pharmacologists, clinicians, pharmacists, and consumers. Since the extent of the information needed will vary from country to country, each country should produce its own sets of minimum information, for patients, using model sets as a standard. Take it at regular intervals, so far as possible every six hours, at the exact time for which it was prescribed.
Capsules: swallow whole with water. Suspension: shake well before measuring the dose and take with water.
Do not take this medicine with milk or any drink containing milk.
STORING THE MEDICINE
Store the medicine in a tightly closed container, protected from light and from temperatures above 30°C.
Discard the medicine after the expiry date. Keep the-medicine out of reach of children.
POSSIBLE PROBLEMS
Tetracycline is much less effective if it is taken with milk-so take it with water.
Tetracycline may make you very sensitive to sunlight-so be cautious about sunbathing.
Tetracycline complicates the use of other medicines such as anticoagulant tablets, preparations containing iron, or any preparation for indigestion containing calcium, magnesium, or aluminium-if you see any doctor other than your own, tell him that you are taking tetracycline; before you use any medicine other than this, ask your pharmacist.
If problems occur do not try to treat them with a home remedy; do not stop the medicine on your own.
Should you have severe or prolonged nausea or heartburn, wind, diarrhoea, sore mouth, or anal irritation-inform your doctor.
Should you have skin rash-tell your doctor promptly. During long-term treatment various body functions may change, and treatment may have to be changed-you therefore need to see your doctor regularly.
Tetracycline should not be used in pregnancy and while breastfeeding-so tell your doctor if you become pregnant. *Important inactive ingredients should be listed here.
